Neotone powder lyophilisate for infusion bottle 1g N4
Condition: New product
969 Items
Rating:
Be the first to write a review!
More info
Description
Powder for solution for infusion Neoton contains phosphocreatine sodium tetrahydrate. Phosphocreatine plays an important role in the energy mechanism of muscle contraction. It is a reserve of energy in myocardial and skeletal muscle cells and is used to re-synthesize adenosine triphosphoric acid (ATP), during hydrolysis of which energy is released to support the process of actomyosin contraction. The lack of energy in cardiomyocytes, associated with the slowing down of oxidative processes, is a key mechanism for the development and progression of myocardial damage. The lack of phosphocreatine leads to a decrease in the force of contraction of the myocardium and its ability to functionally recover.
Active ingredients
Phosphocreatine
Pharmacological effect
Metabolic drug. Phosphocreatine plays an important role in the energy mechanism of muscle contraction. It is a reserve of energy in the cells of the myocardium and skeletal muscles and is used to re-synthesis of ATP, the hydrolysis of which releases energy to ensure the process of actomyosin contraction. The lack of energy in cardiomyocytes, associated with the slowing down of oxidative processes, is a key mechanism for the development and progression of myocardial damage. The lack of phosphocreatine leads to a decrease in the force of contraction of the myocardium and its ability to functionally recover. When myocardial damage occurs, there is a close correlation between the amount of energy-rich phosphorylated compounds in cells, cell viability and their ability to restore contractility. Preclinical and clinical studies have shown the cardioprotective effect of phosphocreatine, which manifests itself in a dose-dependent positive effect on the toxic effect on the myocardium of isoprenaline, thyroxin, emetine, p-nitrophenol, in a positive inotropic effect on glucose deficiency, calcium ions or in case of potassium, and in the case of potassium, or in case of potassium, or in case of potassium, or in case of potassium, or in case of potassium, or in case of potassium, or in case of potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium, or in potassium. inotropic action due to anoxia. In addition, the addition of phosphocreatine to cardioplegic solutions at a concentration of 10 mmol / l improves the cardioprotective effect: - the risk of myocardial ischemia during cardiopulmonary bypass shunting is reduced, - the risk of reperfusion is reducedarrhythmias during infusion before the development of experimental regional ischemia as a result of applying a ligature to the anterior descending branch of the left coronary artery for 15 min, reduces the degradation of ATP and phosphocreatine in myocardial cells, retains the structure of mitochondria and sarcolemma, improves the process of myocardial recovery after cardiac arrest, improves heart failure. administration of potassium in a high dose, and reduces the frequency of reperfusion arrhythmias. Phosphocreatine has a cardioprotective effect in the experiment in myocardial infarction and arrhythmias caused by coronary artery occlusion: retains the adenine nucleotide cell pool by inhibiting enzymes that cause their catabolism, inhibits phospholipid degradation, possibly improves microcirculation in the ischemic zone, which, due to the suppression of mediated ADP platelet aggregation, stabilizes hemodynamic diagrams, stabilizes hemodynamic diagrams, stabilizes hemodynamic diagrams, and hemodynamic diagrams, stabilizes hemodynamic platelets, hemodynamic diagrams, stabilizes hemodynamic platelets, stabilizes hemorrhoids, and improves hemodynamic activity. of heart indicators, has an antiarrhythmic effect, reduces the frequency and duration of ventricular fibrillation and limits the area myocardial infarction.
Pharmacokinetics
After a single intravenous infusion, the maximum concentration of phosphocreatine in the blood plasma is determined for 1-3 minutes. The greatest amount of phosphocreatine is accumulated in skeletal muscle, myocardium, and brain. In the tissues of the liver and lungs, the accumulation of phosphocreatine is insignificant. The release of phosphocreatine is two-phase (fast and slow phases), which is due to its accumulation in the tissues and subsequent elimination from the body into the second phase. T1 / 2 in the fast phase is 30-35 minutes, T1 / 2 in the slow phase is several hours. Excreted by the kidneys.
Indications
In combination therapy: - acute myocardial infarction, - chronic heart failure, - intraoperative myocardial ischemia, - intraoperative lower limb ischemia. In sports medicine - to prevent the development of acute and chronic physical overstrain syndrome and improve the adaptation of athletes to extreme physical exertion.
Dosage and administration
It is used only in / in a drip or in the form of a quick infusion. Acute myocardial infarction1 day: 2-4 g of the drug, diluted in 50 ml of water for injection, in the form of / in a quick infusion followed by a / infusion of 8-16 g in 200 ml of 5% dextrose solution (glucose) for 2 hours. 2 days: 2-4 g in 50 ml of water for injection in / in drip (duration of infusion not less than 30 min) 2 times / day. 3 days: 2 g in 50 ml of water for injection in / in the drip (duration of infusion of at least 30 minutes) 2 times / day.If necessary, a course of infusion of 2 g of the drug 2 times / day can be performed for 6 days. Chronic heart failure Depending on the patient's condition, you can begin treatment with shock doses of 5-10 g of the drug in 200 ml of 5% dextrose (glucose) IV drip at a rate of 4-5 g / h for 3-5 days, and then switch to IV drip (infusion duration of at least 30 minutes) 1-2 g of the drug diluted in 50 ml of water for injection, 2 times / day, within 2-6 weeks or immediately start IV drip of Neotone in maintenance doses x (1-2 g in 50 ml of water for injection 2 times / day for 2-6 weeks). Intraoperative myocardial ischemia A course in / in drip infusions lasting at least 30 minutes for 2 g of the drug in 50 ml of water for injection is recommended. / day within 3-5 days preceding surgery, and within 1-2 days after it. During surgery, Neotone is added to a conventional cardioplegic solution at a concentration of 10 mmol / l or 2.5 g / l immediately before administration. Intraoperative ischemia of the lower extremities 2-4 g of Neotone in 50 ml of water for injection as a fast infusion before surgical intervention followed by intravenous drip of 8-10 g of the drug in 200 ml of 5% dextrose solution (glucose) at a rate of 4-5 g / h during surgery and during reperfusion. In sports medicine for the prevention of Acute and chronic physical overvoltage syndrome and improved adaptation of athletes to extreme physical exertion should be used at a dose of 1 g / day in 50 ml of water for injection in / to a drip (infusion duration of at least 30 minutes) for 3-4 weeks.